Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | huntingtin | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | Get druggable targets OG5_132837 | All targets in OG5_132837 |
Onchocerca volvulus | Huntingtin homolog | Get druggable targets OG5_132837 | All targets in OG5_132837 |
Brugia malayi | hypothetical protein | Get druggable targets OG5_132837 | All targets in OG5_132837 |
Onchocerca volvulus | Huntingtin homolog | Get druggable targets OG5_132837 | All targets in OG5_132837 |
Loa Loa (eye worm) | hypothetical protein | Get druggable targets OG5_132837 | All targets in OG5_132837 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Giardia lamblia | Transglutaminase/protease, putative | 0.0644 | 0.5 | 0.5 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.0644 | 0.5 | 0.5 |
Echinococcus granulosus | Transglutaminase | 0.0644 | 0.5 | 0.5 |
Mycobacterium tuberculosis | Hypothetical protein | 0.0644 | 0.5 | 0.5 |
Mycobacterium tuberculosis | Conserved protein | 0.0644 | 0.5 | 0.5 |
Onchocerca volvulus | 0.0644 | 0.5 | 0.5 | |
Mycobacterium ulcerans | hypothetical protein | 0.0644 | 0.5 | 0.5 |
Mycobacterium leprae | Conserved hypothetical protein | 0.0644 | 0.5 | 0.5 |
Mycobacterium ulcerans | hypothetical protein | 0.0644 | 0.5 | 0.5 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.0644 | 0.5 | 0.5 |
Mycobacterium ulcerans | putative transglutaminase-like protein | 0.0644 | 0.5 | 0.5 |
Mycobacterium leprae | Conserved hypothetical protein | 0.0644 | 0.5 | 0.5 |
Trichomonas vaginalis | peptide N-glycanase, putative | 0.0644 | 0.5 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0644 | 0.5 | 0.5 |
Mycobacterium tuberculosis | Long conserved protein | 0.0644 | 0.5 | 0.5 |
Mycobacterium ulcerans | transglutaminase family protein | 0.0644 | 0.5 | 0.5 |
Giardia lamblia | Hypothetical protein | 0.0644 | 0.5 | 0.5 |
Echinococcus multilocularis | Transglutaminase | 0.0644 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.7375 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 2.6169 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | = 5.6234 um | PUBCHEM_BIOASSAY: qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP). (Class of assay: confirmatory) [Related pubchem assays: 1482, 1471 ] | ChEMBL. | No reference |
Potency (functional) | 22.3872 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b: Cytotox Counterscreen. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588855, AID588860] | ChEMBL. | No reference |
Potency (binding) | = 35.4813 um | PUBCHEM_BIOASSAY: qHTS Assay for Identification of Novel General Anesthetics. In this assay, a GABAergic mimetic model system, apoferritin and a profluorescent 1-aminoanthracene ligand (1-AMA), was used to construct a competitive binding assay for identification of novel general anesthetics (Class of assay: confirmatory) [Related pubchem assays: 2385 (Probe Development Summary for Identification of Novel General Anesthetics), 2323 (Validation apoferritin assay run on SigmaAldrich LOPAC1280 collection)] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.